National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Abiraterone acetate (Zytiga®) for mHSPC

Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).


NCPE Assessment Process Complete
Rapid review commissioned 03/10/2018
Rapid review completed 15/11/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended


The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.